Currency In USD
| Previous Close | 13.1 |
| Open | 13.12 |
| Day High | 13.45 |
| Day Low | 12.7 |
| 52-Week High | 16.93 |
| 52-Week Low | 6.96 |
| Volume | 1.57M |
| Average Volume | 938,735 |
| Market Cap | 703.12M |
| PE | -4.95 |
| EPS | -2.57 |
| Moving Average 50 Days | 13.98 |
| Moving Average 200 Days | 10.7 |
| Change | -0.37 |
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
GlobeNewswire Inc.
Feb 09, 2026 1:00 PM GMT
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected to exceed 500 patients randomized, reflecting strong
4DMT Provides Company Update and Anticipated Development Milestones for 2026
GlobeNewswire Inc.
Jan 07, 2026 1:00 PM GMT
Enrollment in 4D-150 Phase 3 wet AMD clinical trials exceeding expectations; 4FRONT-1 trial remains on track to complete enrollment in Q1 2026, with 381 patients randomized or approved to randomize as of January 6, 20264D-150 PRISM wet AMD 2-year Pha
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data supp